Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice

被引:96
作者
Dash, Prasanta K. [1 ,4 ]
Gendelman, Howard E. [1 ,4 ]
Roy, Upal [1 ,4 ]
Balkundi, Shantanu [1 ,4 ]
Alnouti, Yazen [2 ]
Mosley, Rodney L. [1 ,4 ]
Gelbard, Harris A. [3 ]
McMillan, JoEllyn [1 ,4 ]
Gorantla, Santhi [1 ,4 ]
Poluektova, Larisa Y. [1 ,4 ]
机构
[1] Univ Nebraska Med Ctr, Coll Med, Ctr Neurodegenerat Disorders, Omaha, NE USA
[2] Univ Nebraska Med Ctr, Coll Pharm, Dept Pharmaceut Sci, Omaha, NE USA
[3] Univ Rochester, Sch Med & Dent, Dept Neurol, Ctr Neural Dev & Dis,Child Neurol Div, Rochester, NY 14642 USA
[4] Univ Nebraska Med Ctr, Coll Med, Dept Pharmacol & Expt Neurosci, Omaha, NE USA
基金
美国国家卫生研究院;
关键词
central nervous system; drug biodistribution; HIV-associated neurocognitive disorders; humanized mice; HIV-1; nanoformulated antiretroviral therapy; PROGRESSIVE HIV-1 INFECTION; ATAZANAVIR-RITONAVIR; DRUG-DELIVERY; REGIMEN SIMPLIFICATION; MOUSE; MODEL; PHARMACOKINETICS; MACROPHAGES; SUPPRESSION; LIMITATIONS;
D O I
10.1097/QAD.0b013e328357f5ad
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: Long-acting nanoformulated antiretroviral therapy (nanoART) with improved pharmacokinetics, biodistribution and limited systemic toxicities will likely improve drug adherence and access to viral reservoirs. Design: Atazanavir and ritonavir crystalline nanoART were formulated in a poloxamer-188 excipient by high-pressure homogenization. These formulations were evaluated for antiretroviral and neuroprotective activities in humanized NOD/scid-IL-2Rg(c)(null) (NSG) mice. Methods: NanoART-treated NSG mice were evaluated for drug biodistribution, pharmacodynamics and toxicity. CD34(+) human hematopoietic stem cells were transplanted at birth in replicate NSG mice. The mice were infected with HIV-1(ADA) at 5 months of age. Eight weeks later, the infected animals were treated with weekly subcutaneous injections of nanoformulated ATV and RTV. Peripheral viral load, CD4(+) T-cell counts and lymphoid and brain histopathology and immunohistochemistry tests were performed. Results: NanoART treatments by once-a-week injections reduced viral loads more than 1000-fold and protected CD4(+) T-cell populations. This paralleled high ART levels in liver, spleen and blood that were in or around the human minimal effective dose concentration without notable toxicities. Importantly, examination of infected brain subregions showed that nanoART elicited neuroprotective responses with detectable increases in microtubule-associated protein-2, synaptophysin and neurofilament expression when compared to untreated virus-infected animals. Therapeutic interruptions produced profound viral rebounds. Conclusion: Long-acting nanoART has translational potential with sustained and targeted efficacy and with limited systemic toxicities. Such success in drug delivery and distribution could improve drug adherence and reduce viral resistance in infected people. (c) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
引用
收藏
页码:2135 / 2144
页数:10
相关论文
共 35 条
[1]   Comparative manufacture and cell-based delivery of antiretroviral nanoformulations [J].
Balkundi, Shantanu ;
Nowacek, Ari S. ;
Veerubhotla, Ram S. ;
Chen, Han ;
Martinez-Skinner, Andrea ;
Roy, Upal ;
Mosley, R. Lee ;
Kanmogne, Georgette ;
Liu, Xinming ;
Kabanov, Alexander V. ;
Bronich, Tatiana ;
McMillan, JoEllyn ;
Gendelman, Howard E. .
INTERNATIONAL JOURNAL OF NANOMEDICINE, 2011, 6 :3393-3404
[2]  
Balkundi Shantanu, 2010, J Vis Exp, DOI 10.3791/2460
[3]   Successes, challenges, and limitations of current antiretroviral therapy in low-income and middle-income countries [J].
Bartlett, John A. ;
Shao, John F. .
LANCET INFECTIOUS DISEASES, 2009, 9 (10) :637-649
[4]   The utility of the new generation of humanized mice to study HIV-1 infection: transmission, prevention, pathogenesis, and treatment [J].
Berges, Bradford K. ;
Rowan, Mark R. .
RETROVIROLOGY, 2011, 8
[5]   Pharmacokinetics of Once-Daily Darunavir-Ritonavir and Atazanavir-Ritonavir over 72 Hours following Drug Cessation [J].
Boffito, Marta ;
Jackson, Akil ;
Amara, Alieu ;
Back, David ;
Khoo, Saye ;
Higgs, Chris ;
Seymour, Natalia ;
Gazzard, Brian ;
Moyle, Graeme .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (09) :4218-4223
[6]   Cystatin C, Albuminuria, and 5-Year All-Cause Mortality in HIV-Infected Persons [J].
Choi, Andy ;
Scherzer, Rebecca ;
Bacchetti, Peter ;
Tien, Phyllis C. ;
Saag, Michael S. ;
Gibert, Cynthia L. ;
Szczech, Lynda A. ;
Grunfeld, Carl ;
Shlipak, Michael G. .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2010, 56 (05) :872-882
[7]   Suppression of Human Immunodeficiency Virus Type 1 (HIV-1) Viremia with Reverse Transcriptase and Integrase Inhibitors, CD4+ T-Cell Recovery, and Viral Rebound upon Interruption of Therapy in a New Model for HIV Treatment in the Humanized Rag2-/-γc-/- Mouse [J].
Choudhary, Shailesh K. ;
Rezk, Naser L. ;
Ince, William L. ;
Cheema, Manzoor ;
Zhang, Liguo ;
Su, Lishan ;
Swanstrom, Ronald ;
Kashuba, Angela D. M. ;
Margolis, David M. .
JOURNAL OF VIROLOGY, 2009, 83 (16) :8254-8258
[8]   Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy [J].
Chun, Tae-Wook ;
Nickle, David C. ;
Justement, Jesse S. ;
Meyers, Jennifer H. ;
Roby, Gregg ;
Hallahan, Claire W. ;
Kottilil, Shyam ;
Moir, Susan ;
Mican, Joann M. ;
Mullins, James I. ;
Ward, Douglas J. ;
Kovacs, Joseph A. ;
Mannon, Peter J. ;
Fauci, Anthony S. .
JOURNAL OF INFECTIOUS DISEASES, 2008, 197 (05) :714-720
[9]   Loss of Neuronal Integrity during Progressive HIV-1 Infection of Humanized Mice [J].
Dash, Prasanta K. ;
Gorantla, Santhi ;
Gendelman, Howard E. ;
Knibbe, Jaclyn ;
Casale, George P. ;
Makarov, Edward ;
Epstein, Adrian A. ;
Gelbard, Harris A. ;
Boska, Michael D. ;
Poluektova, Larisa Y. .
JOURNAL OF NEUROSCIENCE, 2011, 31 (09) :3148-3157
[10]   Cytochrome P450 expression and regulation in CYP3A4/CYP2D6 double transgenic humanized mice [J].
Felmlee, Melanie A. ;
Lon, Hoi-Kei ;
Gonzalez, Frank J. ;
Yu, Ai-Ming .
DRUG METABOLISM AND DISPOSITION, 2008, 36 (02) :435-441